相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
50.0%
尚未招募
1
16.7%
招募中
2
33.3%
暂无批准数据
- Dr. Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India Limited for select brands in India, originally signed on February 11, 2022. - The termination was triggered by a change in the controlling shareholding of Novartis India Limited. - Dr. Reddy's will continue to commercialize the affected brands through an extended transition period until September 30, 2026. - The strategic move aims to streamline operations and ensure an orderly market transition for the covered product portfolio.
- Novartis India Limited posted a standalone net profit of ₹32.21 crore for Q1FY26, a 16.59% increase from ₹27.62 crore in the same quarter last year. - Revenue from operations rose 18.6% year-on-year to ₹103.81 crore, while EBITDA margin expanded to 33.6% from 30.02%, reflecting improved operational efficiency. - The company's majority stake (70.68%) is being acquired by WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners, with the open offer closing on 24 June 2026. - New Labour Codes notified in November 2025 led to a ₹79 lakh increase in employee benefit provisions, recognized in the current reporting period.
- Novartis AG has executed a definitive agreement to sell its entire 70.68% controlling stake in Novartis India Limited to a consortium of three investment firms for approximately $345 million. - The transaction automatically triggers a mandatory open offer under SEBI regulations, requiring the acquiring consortium to offer purchase opportunities to all remaining public shareholders. - Novartis India's recent financial performance shows declining trends with Q3 revenue falling 8% year-over-year to ₹859 million and net profit dropping 37% to ₹161 million. - The strategic divestment allows Novartis AG to retain its R&D operations through Novartis Healthcare Private Limited while exiting commercial operations in India's competitive pharmaceutical market.
